Form 4 for PALI PALISADE BIO, INC.
Accepted 2022-08-18 00:00:00 ET · period of report 2022-08-16 · accession 0001493152-22-023511 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-08-18 | 2022-08-16 | PALI | Hallam Thomas | CEO, Dir | P - Purchase | $0.25 | +40.0K | 57.6K | +227% | +$10.0K |
| DM | 2022-08-18 | 2022-08-16 | PALI | Hallam Thomas | CEO, Dir | P - Purchase | $0.00 | +80.0K | 40.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, par value $0.01 | 2022-08-16 | P | A | 40,000 | $0.25 | 57,592 | D | — | — | |
| 2 | Derivative | Series 1 Common Stock Purchase Warrant | 2022-08-16 | P | A | 40,000 | $0.00 | 40,000 | D | $0.25 · — to 2023-08-16 | 40,000 Common Stock | (F2) Represents Series 1 Common Stock Purchase Warrants received as part of the Units purchased by Reporting Person. The Series 1 Warrants are exercisable upon receipt of stockholder approval per Nasdaq rules, which has not been obtained as of the date of this Form 4. |
| 3 | Derivative | Series 2 Common Stock Purchase Warrant | 2022-08-16 | P | A | 40,000 | $0.00 | 40,000 | D | $0.25 · — to 2027-08-16 | 40,000 Common Stock | (F3) Represents Series 2 Common Stock Purchase Warrants received as part of the Units purchased by Reporting Person. The Series 2 Warrants are exercisable upon receipt of stockholder approval per Nasdaq rules, which has not been obtained as of the date of this Form 4. |